MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 Mar 2024 20:40:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 Feb 2024 15:05:01 By Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 Feb 2024 08:15:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

21 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

15 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

01 Feb 2024 08:25:00 By Nasdaq GlobeNewswire

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

30 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

18 Jan 2024 17:10:00 By Nasdaq GlobeNewswire

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

09 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance

21 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

20 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents

20 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

16 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Participate in Stephens Annual Investment Conference

09 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Pricing of Upsized Offering of Common Stock

08 Nov 2023 20:20:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Proposed Offering of $100 Million of Shares of Common Stock

08 Nov 2023 15:10:56 By Nasdaq GlobeNewswire

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

06 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

01 Nov 2023 08:00:00 By Nasdaq GlobeNewswire